VectivBio has initiated a Phase 2 STARS Nutrition study assessing apraglutide in patients with short bowel syndrome and intestinal failure (SBS-IF), specifically targeting colon-in-continuity (CIC) patients. CIC patients, who comprise over half the SBS-IF population, face unique challenges as they have limited treatment options. The trial aims to demonstrate that apraglutide enhances intestinal energy absorption, potentially reducing the need for parenteral support. Initial results on energy absorption are anticipated in the first half of 2022, with the study enrolling approximately 10 patients.
VectivBio announced key leadership changes, appointing Omar Khwaja, M.D., Ph.D., as Chief Medical Officer and Christian Meyer, M.D., Ph.D., as Chief Operating Officer. Both bring over 20 years of experience in drug development and medicine. This move aims to bolster VectivBio's development efforts for apraglutide, currently in a Phase 3 trial for short bowel syndrome, and support its rare disease product portfolio expansion. CEO Luca Santarelli emphasized the importance of these appointments in advancing the company's mission to address significant medical needs.
Summary not available.
VectivBio Holding AG (Nasdaq: VECT) announced the closing of its initial public offering, successfully issuing 8,625,000 ordinary shares at $17.00 each, raising approximately $146.6 million. This offering included the underwriters' full option for an additional 1,250,000 shares. VectivBio, a clinical-stage biopharmaceutical firm, focuses on innovative treatments for severe rare conditions, notably developing the drug apraglutide for gastrointestinal diseases. Shares began trading on Nasdaq on April 9, 2021.
VectivBio Holding AG has announced the pricing of its initial public offering (IPO) of 7,500,000 ordinary shares at $17.00 each, totaling gross proceeds of $127.5 million. The IPO is set to close on April 13, 2021, pending customary conditions, with shares expected to trade on Nasdaq under the symbol 'VECT' starting April 9, 2021. Vectiv has also granted underwriters a 30-day option for an additional 1,125,000 shares. The offering is managed by BofA Securities, SVB Leerink, and Credit Suisse.